Activation_NN of_IN Mitogen-activated_NP Protein_NP Kinase_NP (_( Mitogen-activated_NP Protein_NP Kinase/Extracellular_NP Signal-regulated_NP Kinase_NP )_) Cascade_NP by_IN Aldosterone_NP Aldosterone_NP in_IN some_DT tissues_NNS increases_NNS expression_NN of_IN the_DT mRNA_NN encoding_VBG the_DT small_JJ monomeric_JJ G_NP protein_NN Ki-RasA_NP ._SENT Renal_JJ A6_NP epithelial_JJ cells_NNS were_VBD used_VBN to_TO determine_VB whether_IN induction_NN of_IN Ki-ras_NP leads_VBZ to_TO concomitant_JJ increases_NNS in_IN the_DT total_NN as_RB well_RB as_IN active_JJ levels_NNS of_IN Ki-RasA_NP and_CC whether_IN this_DT then_RB leads_VBZ to_TO subsequent_JJ activation_NN of_IN its_PP$ effector_NN mitogen-activated_JJ protein_NN kinase_NN (_( MAPK/extracellular_JJ signal-regulated_JJ kinase_NN )_) cascade_NN ._SENT The_DT molecular_JJ basis_NN and_CC cellular_JJ consequences_NNS of_IN this_DT action_NN were_VBD specifically_RB investigated_VBN ._SENT We_PP identified_VBD the_DT intron_NN 1-exon_NP 1_CD region_NN (_( rasI/E1_JJ )_) of_IN the_DT mouse_NN Ki-ras_NP gene_NN as_IN sufficient_JJ to_TO reconstitute_VB aldosterone_NN responsiveness_NN to_TO a_DT heterologous_JJ promotor_NP ._SENT Aldosterone_NN increased_VBD reporter_NN gene_NN activity_NN containing_VBG rasI/E1_JJ threefold_RB ._SENT Aldosterone_NN increased_VBD the_DT absolute_JJ and_CC GTP-bound_JJ levels_NNS of_IN Ki-RasA_NP by_IN a_DT similar_JJ extent_NN ,_, suggesting_VBG that_IN activation_NN resulted_VBN from_IN mass_JJ action_NN and_CC not_RB effects_NNS on_IN GTP_NP binding/hydrolysis_NN rates_NNS ._SENT Aldosterone_NN significantly_RB increased_VBD Ki-RasA_NP and_CC MAPK_NP activity_NN as_IN early_JJ as_IN 15_CD min_NN with_IN activation_NN peaking_VBG by_IN 2_CD h_NN and_CC waning_VBG after_IN 4_CD h._JJ Inhibitors_NNS of_IN transcription_NN ,_, translation_NN ,_, and_CC a_DT glucocorticoid_JJ receptor_NN antagonist_NN attenuated_JJ MAPK_NP signaling_VBG ._SENT Similarly_RB ,_, rasI/E1-driven_JJ luciferase_NN expression_NN was_VBD sensitive_JJ to_TO glucocorticoid_JJ receptor_NN blockade_NN ._SENT Overexpression_NN of_IN dominant-negative_JJ RasN17_JJ ,_, addition_NN of_IN antisense_NN Ki-rasA_NP and_CC inhibition_NN of_IN mitogen-activated_JJ protein_NN kinase_NN kinase_NN also_RB attenuated_VBN steroid-dependent_JJ increases_NNS in_IN MAPK_NP signaling_VBG ._SENT Thus_RB ,_, activation_NN of_IN MAPK_NP by_IN aldosterone_NN is_VBZ dependent_JJ ,_, in_IN part_NN ,_, on_IN a_DT genomic_JJ mechanism_NN involving_VBG induction_NN of_IN Ki-ras_NP transcription_NN and_CC subsequent_JJ activation_NN of_IN its_PP$ downstream_JJ effectors_NNS ._SENT This_DT genomic_JJ mechanism_NN has_VBZ a_DT distinct_JJ time_NN course_NN from_IN activation_NN by_IN traditional_JJ mitogens_NNS ,_, such_JJ as_IN serum_NN ,_, which_WDT affect_VBP the_DT GTP-binding_NP state_NN and_CC not_RB absolute_JJ levels_NNS of_IN Ras_NP ._SENT The_DT result_NN of_IN such_PDT a_DT genomic_JJ mechanism_NN is_VBZ that_IN peak_JJ activation_NN of_IN the_DT MAPK_NP cascade_NN by_IN adrenal_JJ corticosteroids_NNS is_VBZ delayed_JJ but_CC prolonged_JJ ._SENT Small_JJ ,_, monomeric_JJ Ras_NP GTP-binding_NP proteins_NNS initiate_VBP pleiotropic_JJ signaling_VBG cascades_NNS to_TO affect_VB many_JJ aspects_NNS of_IN cellular_JJ physiology_NN ._SENT Ras_NP signaling_VBG through_IN the_DT extracellular_JJ signal-regulated_JJ kinase_NN (_( ERK_NP )_) cascade_NN mediated_VBN by_IN mitogen-activated_JJ protein_NN kinases_NNS (_( MAPKs_NP )_) 1/2_CD ,_, for_IN instance_NN ,_, is_VBZ well_RB documented_VBN to_TO play_VB a_DT pivotal_JJ role_NN in_IN cellular_JJ growth_NN and_CC differentiation_NN ._SENT Protein_NN hormones_NNS ,_, which_WDT target_VBP GTP_NP exchange_NN factors_NNS and_CC GTPase-activating_JJ proteins_NNS via_IN plasma_NN membrane_NN receptors_NNS ,_, activate_VBP the_DT MAPK_NP cascade_NN by_IN increasing_VBG the_DT GTP-bound_JJ state_NN of_IN Ras_NP proteins_NNS and_CC not_RB the_DT absolute_JJ levels_NNS of_IN these_DT proteins_NNS ._SENT Thus_RB ,_, the_DT "_`` classic_JJ "_'' paradigm_NN of_IN Ras_NP ->_NP MAPK_NP signaling_VBG involves_VBZ posttranslational_JJ control_NN of_IN Ras_NP ._SENT Emerging_VBG evidence_NN suggests_VBZ that_IN numerous_JJ steroids_NNS ,_, including_VBG aldosterone_NN ,_, also_RB affect_VB Ras_NP signaling_VBG ._SENT The_DT molecular_JJ basis_NN and_CC end_NN effect_NN of_IN this_DT steroid_NN action_NN remain_VBP ,_, for_IN the_DT most_JJS part_NN ,_, not_RB well_RB described_VBN ._SENT Because_IN steroids_NNS control_VBP cell_NN activity_NN through_IN receptors_NNS that_WDT function_VBP as_IN trans-acting_VBG factors_NNS to_TO modulate_VB gene_NN expression_NN ,_, it_PP is_VBZ possible_JJ that_IN steroids_NNS act_VB on_IN the_DT Ras_NP signaling_VBG cascade_NN via_IN a_DT "_`` genomic_JJ "_'' mechanism_NN that_WDT is_VBZ dependent_JJ on_IN transcription_NN and_CC subsequent_JJ translation_NN to_TO increase_VB Ras_NP protein_NN levels_NNS and_CC thus_RB ,_, distinct_JJ from_IN the_DT classic_JJ mechanism_NN ._SENT The_DT current_JJ study_NN ,_, which_WDT investigated_VBD this_DT possibility_NN ,_, identifies_VBZ a_DT novel_JJ paradigm_NN by_IN which_WDT corticosteroid_NN activate_VBP the_DT Ras_NP ->_NN MAPK_NP signaling_VBG cascade_NN ._SENT The_DT adrenal_JJ cortical_JJ steroid_NN hormone_NN aldosterone_NN is_VBZ the_DT major_JJ endocrine_JJ factor_NN regulating_VBG Na+_NP and_CC K+_NP homeostasis_NN ._SENT Aldosterone_NN ,_, consequently_RB ,_, plays_VBZ a_DT central_JJ role_NN in_IN maintaining_VBG electrolyte_NN and_CC water_NN balance_NN ._SENT Aldosterone_NN also_RB plays_VBZ a_DT direct_JJ role_NN in_IN pathological_JJ remodeling_NN of_IN the_DT heart_NN ,_, possibly_RB by_IN promoting_VBG fibrosis_NN and_CC cellular_JJ proliferation_NN both_CC of_IN which_WDT are_VBP generally_RB known_VBN to_TO be_VB impacted_VBN by_IN Ras_NP signaling_VBG via_IN ERK_NP cascades_NNS ._SENT Although_IN the_DT systemic_JJ effects_NNS and_CC target_NN tissues_NNS of_IN aldosterone_NN are_VBP well_RB known_VBN ,_, little_RB is_VBZ actually_RB known_VBN about_IN its_PP$ cellular_JJ mechanisms_NNS of_IN action_NN ._SENT Many_JJ integral_JJ membrane_NN proteins_NNS involved_VBN in_IN epithelial_JJ cell_NN transport_NN ,_, such_JJ as_IN the_DT epithelial_JJ Na+_NP channel_NN (_( ENaC_NP )_) ,_, apical_JJ membrane_NN potassium_NN channel_NN ,_, Na+/Cl-_NP cotransporter_NN ,_, H+/K+-ATPase_NP ,_, and_CC Na+/K+-ATPase_NP are_VBP end_NN effectors_NNS of_IN aldosterone_NN signaling_VBG ._SENT Although_IN aldosterone_NN affects_VBZ cell_NN activity_NN by_IN modulating_VBG gene_NN expression_NN ,_, the_DT expression_NN levels_NNS of_IN these_DT proteins_NNS involved_VBN in_IN transport_NN ,_, however_RB ,_, are_VBP not_RB themselves_PP initially_RB controlled_VBD by_IN the_DT steroid_NN ._SENT This_DT has_VBZ led_VBN to_TO the_DT proposal_NN that_IN aldosterone_NN must_MD control_VB expression_NN of_IN factors_NNS that_WDT initiate_VBP or_CC impinge_VBP upon_IN signal_NN transduction_NN ._SENT Adrenal_JJ corticosteroids_NNS ,_, including_VBG aldosterone_NN ,_, increase_VB the_DT levels_NNS of_IN the_DT small_JJ ,_, monomeric_JJ GTP-binding_NP protein_NN Kirsten_NP Ras_NP (_( Ki-Ras_NP ;_: ;_: ;_: ;_: )_) ._SENT Aldosterone_NN preferentially_RB increases_VBZ expression_NN in_IN epithelia_NN of_IN the_DT A_NP splice_NN variant_NN of_IN Ki-Ras_NP via_IN control_NN of_IN transcription_NN with_IN induction_NN of_IN Ki-ras_NP mRNA_NP being_VBG a_DT primary_JJ response_NN to_TO steroid_NN that_WDT is_VBZ independent_JJ of_IN de_NP novo_NP protein_NN synthesis_NN and_CC begins_VBZ within_IN 30_CD min_NN after_IN steroid_NN addition_NN ._SENT Induction_NN of_IN Ki-RasA_NP is_VBZ necessary_JJ and_CC sufficient_JJ for_IN aldosterone_NN action_NN ,_, in_IN part_NN ,_, on_IN Na+_NP transport_NN ._SENT In_IN addition_NN ,_, Ki-RasA_NP activates_VBZ ENaC_NP when_WRB both_DT proteins_NNS are_VBP overexpressed_VBN in_IN a_DT heterologous_JJ system_NN and_CC increases_VBZ the_DT open_JJ probability_NN of_IN this_DT channel_NN in_IN native_JJ epithelia_NN ._SENT Consequently_RB ,_, Ki-RasA_NP is_VBZ a_DT likely_JJ candidate_NN in_IN some_DT instances_NNS to_TO transduce_VB information_NN form_VB the_DT nucleus_NN to_TO final_JJ effectors_NNS in_IN response_NN to_TO aldosterone_NN ._SENT Induction_NN of_IN Ras_NP expression_NN by_IN steroids_NNS may_MD impact_VB more_RBR than_IN just_RB ENaC_JJ and_CC epithelial_JJ transport_NN for_IN glucocorticoids_NNS and_CC estrogen_NN increase_NN Ras_NP expression_NN in_IN mammary_JJ epithelia_NN with_IN enhanced_JJ expression_NN possibly_RB being_VBG associated_VBN with_IN tumor_NN formation_NN and_CC metastasis_NN ._SENT Indeed_RB ,_, it_PP has_VBZ long_RB been_VBN recognized_VBN that_IN in_IN cells_NNS that_WDT lack_VBP mutant_JJ Ras_NP ,_, elevated_VBD levels_NNS of_IN normal_JJ Ras_NP can_MD lead_VB to_TO cell_NN growth_NN and/or_CC transformation_NN ,_, presumably_RB through_IN inappropriate_JJ stimulation_NN of_IN Ras_NP effector_NN cascades_NNS ._SENT This_DT suggests_VBZ that_IN through_IN mass_JJ action_NN ,_, induction_NN of_IN Ras_NP leads_VBZ to_TO activation_NN of_IN this_DT protein_NN and_CC subsequent_JJ signaling_VBG ._SENT The_DT general_JJ consequences_NNS and_CC in_IN particular_JJ those_NNS associated_VBN with_IN cell_NN signaling_VBG of_IN steroid-dependent_JJ induction_NN of_IN Ki-ras_NP are_VBP not_RB well_RB understood_VBN ._SENT It_PP also_RB is_VBZ not_RB clear_JJ whether_IN increases_NNS in_IN Ki-RasA_NP levels_NNS in_IN response_NN to_TO aldosterone_NN result_NN from_IN actions_NNS mediated_VBN by_IN nuclear_JJ receptors_NNS and_CC whether_IN steroid-sensitive_JJ increases_NNS in_IN Ki-RasA_NP result_NN in_IN concomitant_JJ increases_NNS in_IN functional_JJ GTP-bound_NP Ki-RasA_NP ._SENT Similar_JJ to_TO the_DT other_JJ Ras_NP proteins_NNS (_( Ha-Ras_NP ,_, N-Ras_NP ,_, and_CC Ki-RasB_NP )_) ,_, active_JJ Ki-RasA_NP initiates_VBZ many_JJ different_JJ intracellular_JJ signaling_VBG cascades_NNS ,_, including_VBG the_DT MAPK_NP cascade_NN ._SENT This_DT cascade_NN is_VBZ known_VBN to_TO affect_VB several_JJ aldosterone-target_NN proteins_NNS ,_, such_JJ as_IN ENaC_NP ,_, Na+/K+-ATPase_NP ,_, Na+/H+_NP exchanger_NN ,_, Na+/Cl-_NP ,_, and_CC Na+/bicarbonate_JJ cotransport_NN ;_: and_CC Na+/Ca2+_NP exchange_NN proteins_NNS ._SENT Thus_RB ,_, the_DT MAPK_NP cascade_NN may_MD play_VB a_DT pivotal_JJ role_NN in_IN signaling_VBG aldosterone_NN action_NN secondarily_RB to_TO stimulation_NN of_IN Ki-RasA_NP or_CC may_MD ultimately_RB be_VB involved_VBN in_IN a_DT negative_JJ feedback_NN pathway_NN initiated_VBN by_IN this_DT steroid_NN ._SENT The_DT current_JJ work_NN tested_VBD the_DT hypothesis_NN that_IN aldosterone-stimulated_JJ Ki-RasA_NP activates_VBZ the_DT MAPK_NP cascade_NN in_IN renal_JJ epithelia_NN ._SENT In_IN addition_NN ,_, we_PP asked_VBD whether_IN Ki-RasA_NP and_CC the_DT MAPK_NP cascade_NN are_VBP activated_VBN in_IN response_NN to_TO aldosterone_NN via_IN nuclear_JJ steroid_NN receptors_NNS ,_, and_CC whether_IN increases_NNS in_IN Ki-RasA_NP expression_NN in_IN response_NN to_TO steroid_NN result_NN in_IN increases_NNS in_IN functional_JJ Ki-RasA:GTP_NP levels_NNS ._SENT Through_IN the_DT course_NN of_IN this_DT work_NN ,_, we_PP also_RB investigated_VBD possible_JJ molecular_JJ mechanisms_NNS by_IN which_WDT aldosterone_NN induces_VBZ Ki-Ras_NP expression_NN and_CC compared_VBN aldosterone_NN effects_NNS on_IN Ki-Ras_NP ->_NP MAPK_NP signaling_VBG with_IN that_DT of_IN a_DT traditional_JJ mitogen_NN ,_, such_JJ as_IN serum_NN ._SENT Cell_NN Culture_NP |_SYM All_DT experiments_NNS were_VBD performed_VBN with_IN renal_JJ A6_NP epithelial_JJ cells_NNS (_( passages_NNS 75_CD --_: 81_CD ;_: American_NP Type_NP Culture_NP Collection_NP ,_, Manassas_NP ,_, VA_NP )_) ._SENT Cells_NNS were_VBD cultured_VBN on_IN polycarbonate_JJ supports_NNS (_( Transwell-Clear_NP Inserts_NP ,_, pore_NN size_NN 0.4_CD muM_NN ,_, growth_NN area_NN 4.7_CD cm2_NN ;_: ,_, Cambridge_NP ,_, MA_NP )_) and_CC allowed_VBN to_TO form_VB polar_JJ monolayers_NNS by_IN using_VBG standard_JJ methods_NNS described_VBN previously_RB (_( ,_, ,_, ,_, )_) ._SENT In_IN brief_NN ,_, cells_NNS were_VBD maintained_VBN at_IN 26C_JJ in_IN 4_CD %_NN CO2_NN with_IN complete_JJ amphibian_JJ medium_NN (_( 3/10_CD Coon_NP 's_POS F-12_NP ,_, 7/10_CD Leibovitz_NP 's_POS L-15_NP )_) supplemented_VBD with_IN fetal_JJ bovine_JJ serum_NN (_( 10_CD %_NN )_) ._SENT Basic_JJ medium_NN was_VBD devoid_JJ of_IN serum_NN and_CC aldosterone_NN ._SENT High-resistance_NP (_( >2_NP KOmega_NP )_) ,_, polarized_VBN A6_NP cell_NN monolayers_NNS were_VBD used_VBN for_IN all_DT experiments_NNS ._SENT To_TO observe_VB the_DT full_JJ action_NN of_IN aldosterone_NN ,_, confluent_JJ cells_NNS were_VBD treated_VBN with_IN basic_JJ media_NNS for_IN 48_CD to_TO 72_CD h_NN before_IN experimentation_NN ._SENT Molecular_JJ Biology_NN |_SYM Plasmid_NP Preparation_NP and_CC Isolation_NP of_IN Ki-ras_NP Intron_NP 1-Exon_NP 1_CD ._SENT |_SYM The_DT pMMrasDN_NN plasmid_NN was_VBD a_DT kind_NN gift_NN form_NN Dr._NP G._NP Firestone_NP (_( University_NP of_IN California_NP at_IN Berkeley_NP ,_, Berkeley_NP ,_, CA_NP )_) ._SENT In_IN brief_NN ,_, this_DT construct_NN allows_VBZ glucocorticoid-inducible_JJ expression_NN of_IN dominant-negative_JJ Ha-RasN17_JJ ._SENT Similar_JJ to_TO that_WDT described_VBD previously_RB by_IN the_DT Firestone_NP laboratory_NN for_IN Con8_NP rat_VBP mammary_JJ epithelial_JJ cells_NNS ,_, this_DT construct_NN in_IN conjunction_NN with_IN G418_NP selection_NN was_VBD used_VBN to_TO create_VB clonal_JJ A6_NP cell_NN lines_NNS stably_RB expressing_VBG inducible_JJ dominant-negative_NN RasN17_JJ ._SENT The_DT firefly_NN luciferase_NN reporter_NN plasmid_NN pGL2-TK_NN was_VBD generated_VBN by_IN subcloning_VBG the_DT minimal_JJ herpes_NN simplex_JJ virus_NN thymidine_NN kinase_NN promotor_NP from_IN pRL-TK_NP (_( Promega_NP ,_, Madison_NP ,_, WI_NP )_) into_IN pGL2_JJ Basic_NP Vector_NP (_( Promega_NP )_) with_IN HindIII_NP and_CC BglII_NP ._SENT (_( pGL2-TK_NN was_VBD a_DT kind_NN gift_NN from_IN Dr._NP A._NP Firulli_NP ,_, University_NP of_IN Texas_NP ,_, San_NP Antonio_NP ,_, TX_NP ._SENT )_) The_DT control_NN pRL-CMV_NP plasmid_NP contains_VBZ the_DT cytomegalovirus_NN promotor_NP upstream_RB of_IN Renilla_NP luciferase_NP (_( Promega_NP )_) ._SENT Mouse_NP c-Ki-ras2_NP exon_NN 1_CD plus_CC its_PP$ 5'-flanking_JJ region_NN (_( intron_NN 1-exon_NP 1_CD region_NN ;_: nucleic_JJ acids_NNS -165_CD --_: 153_CD as_RB labeled_VBN from_IN the_DT adenosine_NN of_IN the_DT translation_NN start_NN codon_NN ATG_NP in_IN exon_NN 1_CD ;_: see_VBP GenBank_NP accession_NN numbers_NNS ,_, 52798_CD ,_, ,_, and_CC ;_: ;_: )_) were_VBD amplified_VBN with_IN a_DT standard_JJ polymerase_NN chain_NN reaction_NN by_IN using_VBG mouse_NN whole_JJ tail_JJ genomic_JJ DNA_NN and_CC the_DT 5'-ATGCGGTACCGACTTACAGGTTACTC_NN (_( incorporating_VBG KpnI_NP site_NN ,_, underlined_VBN )_) and_CC 5'-GCATCTCGAGCTGCCGTCCTTTACAAGCG_JJ (_( incorporating_VBG XhoI_NP site_NN ,_, underlined_VBN )_) upstream_JJ and_CC downstream_JJ primers_NNS ,_, respectively_RB ._SENT The_DT 321-base_JJ pair_NN product_NN from_IN this_DT polymerase_NN chain_NN reaction_NN was_VBD subcloned_VBN into_IN pGL2-TK_NN with_IN KpnI_NP and_CC XhoI_NP to_TO produce_VB pGL2-TK-rasI/E1_JJ ._SENT Luciferase_NP Reporter_NP Gene_NP Assay_NP ._SENT |_SYM A_DT quantitative_JJ assay_NN with_IN a_DT Renilla_NP luciferase_NN internal_JJ control_NN was_VBD used_VBN to_TO measure_VB the_DT firefly_NN luminescent_JJ signal_NN in_IN A6_NP cells_NNS overexpressing_VBG reporter_NN genes_NNS ._SENT In_IN brief_NN ,_, A6_NP cells_NNS plated_VBN at_IN 80_CD %_NN confluence_NN on_IN 100-_CD x_SYM 20-mm2_JJ culture_NN dishes_NNS were_VBD transfected_VBN with_IN 100_CD ng_NNS of_IN pRL-CMV_NN in_IN addition_NN to_TO 3_CD mug_NN of_IN the_DT firefly_NN luciferase_NN reporter_NN plasmid_NN (_( either_CC pGL2-TK_NN or_CC pGL2-TK-rasI/E1_JJ )_) by_IN using_VBG the_DT LipofectAMINE_NP Plus_NP (_( Invitrogen_NP ,_, Carlsbad_NP ,_, CA_NP )_) system_NN per_IN the_DT manufacturer_NN 's_POS instructions_NNS with_IN the_DT exception_NN that_IN cells_NNS were_VBD exposed_VBN to_TO transfection_NN reagents_NNS for_IN similar8_JJ h._NP Twenty-four_NP hours_NNS after_IN transfection_NN and_CC 24_CD h_NN before_IN performing_VBG assay_NN ,_, cells_NNS were_VBD replated_VBN in_IN a_DT 96-well_NP culture_NN plate_NN ._SENT Luciferase_NN activity_NN then_RB was_VBD measured_VBN with_IN the_DT Dual-Luciferase_NP Reporter_NP assay_NN system_NN (_( Promega_NP )_) per_IN the_DT manufacturer_NN 's_POS instructions_NNS directly_RB following_VBG the_DT experimental_JJ treatment_NN period_NN (_( i.e._FW ,_, exposure_NN to_TO 1.5_CD muM_NN aldosterone_NN for_IN 4_CD h._NN )_) and_CC 1-h_NP extract_NN preparation_NN period_NN required_VBN with_IN passive_JJ lysis_NN buffer_NN (_( see_VB Dual-Luciferase_NP Reporter_NP instructions_NNS )_) ._SENT An_DT MLX_NP microtiter_NN plate_NN luminometer_NN (_( Dynatech_NP Labs_NP ,_, Chantilly_JJ ,_, VA_NP )_) was_VBD used_VBN to_TO record_VB luminescent_JJ signal_NN ._SENT For_IN these_DT experiments_NNS ,_, all_DT firefly_NN luciferase_NN activity_NN data_NNS are_VBP normalized_VBN to_TO the_DT internal_JJ Renilla_NP luciferase_NN control_NN ._SENT Biochemistry_NN |_SYM Western_NP Blot_NP Analysis_NP ._SENT |_SYM Whole_NP A6_NP cell_NN lysate_NNS was_VBD extracted_VBN after_IN three_CD washes_VBZ with_IN Tris-buffered_JJ saline_NN by_IN using_VBG standard_JJ procedures_NNS ._SENT Cells_NNS were_VBD scraped_VBN and_CC then_RB maintained_VBN for_IN 1_CD --_: 2_CD h_NN at_IN 4C_JJ in_IN gentle_JJ lysis_NN buffer_NN (_( GLB_NP )_) (_( 76_CD mM_NP NaCl_NP ,_, 50_CD mM_NP HCl-Tris_NP ,_, 2_CD mM_NP EGTA_NP plus_CC 1_CD %_NN Nonidet_NP P-40_NP ,_, and_CC 10_CD %_NN glycerol_NN ,_, pH_NN 7.4_CD )_) and_CC protease_NN inhibitors_NNS (_( phenylmethylsulfonyl_NN fluoride_NN ,_, leupeptin_NN ,_, tosylphenylalanyl_NN chloromethyl_NN ketone_NN ,_, and_CC 1-chloro-3-tosylamido-7-amino-2-heptanone_JJ )_) ._SENT For_IN Western_JJ blot_NN analysis_NN of_IN phosphorylated_JJ proteins_NNS ,_, GLB_NP was_VBD supplemented_VBN with_IN 0.1_CD mM_NP NaPPi_NP ,_, 0.5_CD mM_NP NaF_NP ,_, 0.1_CD mM_NP Na2MoO4_NP ,_, 0.1_CD mM_NP ZnCl2_NP ,_, and_CC 0.04_CD mM_NP Na3VO4_NP prepared_VBD fresh_JJ from_IN 1000x_NP stocks_NNS ._SENT After_IN clearing_VBG cellular_JJ debris_NN ,_, standardizing_VBG total_JJ protein_NN concentration_NN ,_, and_CC addition_NN of_IN Laemmli_NP sample_NN buffer_NN (_( 0.005_CD %_NN bromphenol_NN blue_JJ ,_, 10_CD %_NN glycerol_NN ,_, 3_CD %_NN SDS_NP ,_, 1_CD mM_NP EDTA_NP ,_, 77_CD mM_NP HCl-Tris_NP ,_, and_CC 20_CD mM_NP dithiothreitol_NN )_) ,_, lysates_NNS were_VBD heated_VBN to_TO 85C_JJ for_IN 10_CD min_NN ._SENT Proteins_NNS were_VBD then_RB separated_VBN by_IN standard_JJ SDS-PAGE_NN and_CC subsequently_RB electrophoretically_RB transferred_VBN to_TO nitrocellulose_NN (_( 0.2_CD muM_NN )_) ._SENT Western_JJ blot_NN analysis_NN was_VBD performed_VBN using_VBG standard_JJ techniques_NNS and_CC appropriate_JJ antibodies_NNS (_( ,_, ,_, ,_, ;_: see_VB below_IN ;_: primary_JJ and_CC secondary_JJ antibodies_NNS were_VBD used_VBN at_IN 1/1000_CD and_CC 1/20000_CD ,_, respectively_RB )_) ._SENT Tween_NP 20_CD (_( 0.1_CD %_NN )_) and_CC 5_CD %_NN dried_VBD milk_NN (_( Carnation_NP )_) were_VBD used_VBN as_IN blocking_VBG reagents_NNS ._SENT Band_NN intensity_NN was_VBD quantified_VBN with_IN densitometric_JJ scanning_VBG using_VBG Sigmagel_NP (_( Jandel_NP Scientific_NP ,_, Costa_NP Madre_NP ,_, CA_NP )_) ._SENT When_WRB possible_JJ ,_, the_DT flood_NN configuration_NN with_IN the_DT highest_JJS practical_JJ threshold_NN was_VBD used_VBN to_TO measure_VB band_NN density_NN ._SENT Western_JJ blots_NNS were_VBD often_RB stripped_VBN of_IN primary_JJ and_CC secondary_JJ antibody_NN to_TO subsequently_RB reprobe_VB with_IN a_DT control_NN antibody_NN ._SENT All_DT Western_JJ blots_NNS were_VBD stripped_VBN in_IN 100_CD mM_NNS 2-mercaptoethanol_JJ ,_, 62.5_CD mM_NP Tris-HCl_NP ,_, pH_NN 6.7_CD ,_, and_CC 2_CD %_NN SDS_NP for_IN 30_CD min_NN at_IN 55C_NN with_IN constant_JJ agitation_NN ._SENT After_IN removal_NN of_IN antibodies_NNS ,_, nonspecific_JJ interactions_NNS were_VBD reblocked_VBN by_IN incubating_VBG in_IN TBS-Tween_NP ,_, 5_CD %_NN milk_NN for_IN 2_CD h_NN before_IN reprobing_VBG with_IN primary_JJ antibody_NN ._SENT Ras:GTP_NP Assay_NP ._SENT |_SYM Raf-1_NP RBD_NP agarose_NN was_VBD from_IN Upstate_NP Biotechnology_NP (_( Lake_NP placid_JJ ,_, NY_NP )_) ._SENT This_DT immobilized_VBN fusion_NN protein_NN corresponds_VBZ to_TO the_DT human_JJ Raf-1_NP Ras_NP binding_JJ domain_NN (_( RBD_NP )_) (_( residues_NNS 1_CD --_: 149_CD )_) ._SENT Raf-1_NP RBD_NP binds_VBZ Ras_NP complexed_NP with_IN GTP_NP ._SENT Pull-down_JJ experiments_NNS were_VBD performed_VBN in_IN 400_CD mul_NN (_( 0.4_CD mg_NN of_IN total_JJ protein_NN )_) of_IN whole_JJ A6_NP cell_NN lysate_NNS isolated_VBN with_IN GLB_NP ._SENT Lysates_NNS were_VBD incubated_VBN with_IN 30_CD mul_NN of_IN Raf-1_NP RBD_NP agarose_NN overnight_RB (_( at_IN 4C_JJ and_CC with_IN constant_JJ agitation_NN )_) ;_: pellets_NNS were_VBD washed_VBN five_CD times_NNS with_IN 2_CD volumes_NNS of_IN fresh_JJ GLB_NP each_DT time_NN for_IN a_DT total_JJ wash_NN time_NN of_IN 2_CD h_NN ;_: and_CC after_IN resuspending_NN in_IN sample_NN buffer_NN and_CC heating_NN ,_, Raf-1_NP RBD_NP agarose_NN precipitated_VBD proteins_NNS were_VBD separated_VBN by_IN SDS-PAGE_NP and_CC Ki-RasA:GTP_NP identified_VBD by_IN immunoblotting_NN ._SENT MAPK_NP Assay_NP ._SENT |_SYM MAPK_NP activity_NN in_IN lysates_NNS prepared_VBN from_IN cells_NNS treated_VBN with_IN and_CC without_IN aldosterone_NN was_VBD assayed_VBN by_IN quantifying_VBG phosphorylation_NN of_IN exogenous_JJ myelin_NN basic_JJ protein_NN (_( MBP_NP )_) ._SENT MAPK_NP activity_NN was_VBD measured_VBN in_IN whole_JJ A6_NP cell_NN lysate_NNS (_( 2_CD mg/ml_NN )_) extracted_VBN in_IN the_DT presence_NN of_IN phosphatase_NN inhibitors_NNS as_RB described_VBD above_IN ._SENT MAPK_NP activity_NN was_VBD measured_VBN for_IN 30_CD min_NN at_IN 30C_JJ in_IN the_DT following_VBG assay_NN dilution_NN buffer_NN (_( ADB_NP ;_: Upstate_NP Biotechnology_NP )_) :_: 20_CD mM_NP MOPS_NP pH_NN 7.2_CD ,_, 25_CD mM_NP beta-glycerophosphate_NN ,_, 5_CD mM_NP EGTA_NP ,_, 0.4_CD mM_NP MnCl2_NP ,_, 0.4_CD mM_NP CaCl2_NP ,_, 1_CD mM_NP sodium_NN orthovanadate_NNS ,_, and_CC 1_CD mM_NP dithiothreitol_NN ._SENT The_DT final_JJ reaction_NN contained_VBD 10_CD mul_NN of_IN substrate_NN cocktail_NN (_( from_IN stock_NN of_IN 2_CD mg/ml_NN dephosphorylated_JJ MBP_NP in_IN ADB_NP )_) ,_, 10_CD mul_NN of_IN inhibitor_NN cocktail_NN (_( from_IN stock_NN of_IN 20_CD muM_NN PKC_NP inhibitor_NN peptide_NN ,_, 2_CD muM_NN PKA_NP inhibitor_NN peptide_NN ,_, and_CC 20_CD muM_NN compound_NN R24571_NP in_IN ABD_NP )_) ,_, 10_CD mul_NN of_IN A6_NP cell_NN extract_NN ,_, and_CC 10_CD mul_NN of_IN Mg2+/ATP_NP cocktail_NN (_( from_IN a_DT stock_NN of_IN 75_CD mM_NP MgCl2_NP ,_, 500_CD muM_NN ATP_NP in_IN ADB_NP )_) ._SENT Reactions_NNS were_VBD initiated_VBN with_IN Mg2+/ATP_NP and_CC terminated_VBN with_IN Laemmli_NP sample_NN buffer_NN (_( described_VBN above_IN )_) ._SENT Phosphorylation_NN of_IN MBP_NP (_( in_IN 10_CD mul_NN of_IN final_JJ reaction_NN )_) was_VBD assessed_VBN after_IN SDS-PAGE_NP by_IN immunoblot_NN analysis_NN with_IN a_DT specific_JJ anti-phospho-MBP_NN antibody_NN ._SENT Electrophysiology_NN |_SYM Transepithelial_NP Na+_NP current_NN was_VBD calculated_VBN as_IN described_VBN previously_RB (_( ,_, ,_, ,_, )_) ,_, from_IN Ohm_NP 's_POS law_NN as_IN the_DT ratio_NN of_IN transepithelial_JJ voltage_NN to_TO transepithelial_JJ resistance_NN under_IN open_JJ circuit_NN conditions_NNS by_IN using_VBG a_DT Millicel_NP Electrical_NP Resistance_NP System_NP with_IN dual_JJ Ag/AgCl_NP pellet_NN electrodes_NNS (_( Millipore_NP ,_, Bedford_NP ,_, MA_NP )_) to_TO measure_VB voltage_NN and_CC resistance_NN ._SENT Materials_NPS |_SYM All_DT reagents_NNS unless_IN indicated_JJ otherwise_RB were_VBD from_IN either_DT BIOMOL_NP Research_NP Laboratories_NPS (_( Plymouth_NP Meeting_NP ,_, PA_NP )_) ,_, Calbiochem_NP (_( San_NP Diego_NP ,_, CA_NP )_) ,_, Invitrogen_NP ,_, or_CC Sigma-Aldrich_NP (_( St._NP Louis_NP ,_, MO_NP )_) ._SENT Phosphorothiate_JJ oligonucleotides_NNS were_VBD synthesized_VBN by_IN the_DT Emory_NP University_NP Microchemical_NP Facility_NP and_CC stored_VBD frozen_VBN as_IN 10_CD mM_NNS (_( in_IN water_NN )_) stocks_NNS ._SENT Aldosterone_NN ,_, dexamethasone_NN ,_, and_CC mifepristone_NN (_( RU486_NP )_) were_VBD stored_VBN frozen_VBN as_IN 1.5_CD ,_, 0.1_CD ,_, and_CC 1.0_CD mM_NNS (_( in_IN dimethyl_JJ sulfoxide_NN [_SYM DMSO_NP ]_SYM )_) stocks_NNS ._SENT Cycloheximide_NP (_( in_IN MeOH_NP )_) and_CC emetine_NN (_( in_IN H2O_NP )_) were_VBD stored_VBN frozen_VBN as_IN 1.0-mg/ml_JJ stocks_NNS ._SENT Actinomycin_NN D_NP was_VBD stored_VBN at_IN 4C_JJ as_IN a_DT 1.0-ng/ml_JJ (_( in_IN MeOH_NP )_) stock_NN ._SENT PD-98059_NP and_CC U-0126_NP were_VBD prepared_VBN fresh_JJ (_( in_IN DMSO_NP )_) before_IN each_DT experiment_NN at_IN stock_NN concentrations_NNS of_IN 10_CD and_CC 5_CD mM_NNS ,_, respectively_RB ._SENT All_DT reagents_NNS used_VBN for_IN Western_JJ blot_NN analysis_NN unless_IN noted_VBD otherwise_RB were_VBD from_IN (_( Hercules_NP ,_, CA_NP )_) and_CC (_( Rockford_NP ,_, IL_NP )_) ._SENT For_IN each_DT lysate_NN ,_, protein_NN concentration_NN was_VBD determined_VBN with_IN the_DT bicinchoninic_JJ acid_JJ protein_NN assay_NN ._SENT Kodak_NP BioMax_NP Light-1_NP film_NN and_CC Chemiluminescence_NP Reagents_NP Plus_NP (_( PerkinElmer_NP Life_NP Sciences_NPS ,_, Boston_NP ,_, MA_NP )_) were_VBD used_VBN to_TO develop_VB Western_JJ blots_NNS ._SENT Antibodies_NNS |_SYM The_DT rabbit_NN polyclonal_JJ anti-MAPK_NP 1/2_CD (_( Erk_NP 1/2-CT_NP )_) antibody_NN was_VBD from_IN Upstate_NP Biotechnology_NP ._SENT The_DT mouse_NN monoclonal_NN anti-c-Raf-1_JJ antibody_NN was_VBD from_IN Transduction_NP Laboratories_NPS (_( Lexington_NP ,_, KY_NP )_) ._SENT The_DT rabbit_NN polyclonal_JJ anti-MKP-1_NN (_( V-15_NP ;_: MAPK_NP phosphatase_NN )_) ,_, anti-Fra-2_NP (_( L-15_NP )_) ,_, and_CC anti-K-Ras2A_NN antibodies_NNS were_VBD from_IN Santa_NP Cruz_NP Biotechnology_NP (_( Santa_NP Cruz_NP ,_, CA_NP )_) ._SENT This_DT latter_JJ antibody_NN recognizes_VBZ only_RB the_DT Ki-RasA_NP isoform_NN of_IN Ras_NP proteins_NNS ._SENT The_DT mouse_NN monoclonal_NN anti-v-Ha-Ras_NNS antibody_NN was_VBD from_IN Oncogene_NN Science_NP (_( Cambridge_NP ,_, MA_NP )_) ._SENT This_DT antibody_NN recognizes_VBZ all_DT isoforms_NNS of_IN Ras_NP protein_NN ,_, including_VBG Ha-Ras_NP ,_, Ki-RasA_NP ,_, Ki-RasB_NP ,_, and_CC N-Ras_NP ._SENT All_DT phospho-specific_JJ antibodies_NNS were_VBD from_IN Cell_NP Signaling_NP Technologies_NPS (_( Beverly_NP ,_, MA_NP )_) ._SENT All_DT secondary_JJ horseradish_NN peroxidase-conjugated_JJ antibodies_NNS were_VBD from_IN Kirkegaard_NP and_CC Perry_NP Laboratories_NPS (_( Gaithersburg_NP ,_, MD_NP )_) ._SENT Statistics_NPS |_SYM All_DT values_NNS reported_VBD as_RB mean_VB +-_NN SEM_NP ._SENT Statistical_JJ significance_NN (_( p_NN <=_NN 0.05_CD )_) was_VBD determined_VBN using_VBG the_DT t_NN test_NN for_IN differences_NNS in_IN mean_JJ values_NNS ,_, and_CC a_DT one-way_JJ analysis_NN of_IN variance_NN in_IN conjunction_NN with_IN the_DT Student-Newman-Keuls_NNS test_NN for_IN multiple_JJ comparisons_NNS ._SENT Aldosterone_NN Increases_NNS Absolute_NP and_CC Active_NP GTP-bound_NP Levels_NP of_IN Ki-RasA_NP |_SYM Aldosterone_NN via_IN transcriptional_JJ control_NN increases_VBZ Ki-rasA_NP mRNA_NP and_CC Ki-RasA_NP protein_NN levels_NNS in_IN renal_JJ A6_NP epithelial_JJ cells_NNS ._SENT Experiments_NNS in_IN Figure_NP tested_VBD the_DT hypothesis_NN that_IN aldosterone_NN in_IN these_DT cells_NNS also_RB increases_VBZ the_DT amount_NN of_IN active_JJ Ki-RasA_NP ._SENT Activated_VBN Ras_NP bound_VBN by_IN GTP_NP interacts_VBZ with_IN the_DT RBD_NN of_IN Raf_NP ._SENT The_DT representative_JJ Western_JJ blots_NNS of_IN Figure_NN A_DT show_NN that_IN the_DT addition_NN of_IN aldosterone_NN for_IN 3_CD h_NN to_TO A6_NP cell_NN monolayers_NNS markedly_RB increased_VBN Ki-RasA_NP (_( middle_NN )_) and_CC Ki-RasA:GTP_NP levels_NNS (_( bottom_NN )_) ,_, but_CC had_VBD little_JJ effect_NN on_IN total_JJ Ras_NP levels_NNS (_( top_JJ )_) ._SENT It_PP is_VBZ known_VBN that_IN Ki-RasA_NP is_VBZ expressed_VBN at_IN levels_NNS much_RB lower_JJR than_IN other_JJ Ras_NP isoforms_NNS ._SENT Thus_RB ,_, the_DT lack_NN of_IN a_DT marked_JJ change_NN in_IN total_JJ Ras_NP was_VBD not_RB unexpected_JJ ._SENT For_IN these_DT experiments_NNS ,_, Ras:GTP_NP was_VBD isolated_VBN using_VBG GST-RBD_JJ agarose_NN from_IN whole_JJ cell_NN lysates_NNS from_IN cells_NNS treated_VBN with_IN vehicle_NN (_( CON_NP ;_: 0.1_CD %_NN DMSO_NP )_) and_CC aldosterone_NN (_( ALDO_NP ;_: 1.5_CD muM_NN )_) for_IN 3_CD h._NN After_IN isolating_VBG total_JJ cellular_JJ Ras:GTP_NP ,_, Ki-RasA:GTP_NP was_VBD identified_VBN with_IN anti-K-Ras2A_NN antibody_NN ,_, which_WDT reacts_VBZ only_RB with_IN Ki-RasA_NP ._SENT Total_JJ Ras_NP protein_NN was_VBD identified_VBN with_IN the_DT anti-v-Ha-Ras_NP antibody_NN ,_, which_WDT is_VBZ reactive_JJ with_IN Ki-RasA_NP and_CC B_NP ,_, Ha-Ras_NP ,_, and_CC N-Ras_NP isoforms_NNS ._SENT The_DT summary_NN graph_NN in_IN Figure_NP B_NP shows_VBZ the_DT relative_JJ change_NN in_IN response_NN to_TO aldosterone_NN for_IN the_DT levels_NNS of_IN Ras_NP (_( 1.6_CD +-_NN 0.2_CD ,_, n_NN =_SYM 11_CD )_) ,_, Ki-RasA_NP (_( 3.1_CD +-_NN 0.4_CD ,_, n_NN =_SYM 8_CD )_) ,_, and_CC Ki-RasA:GTP_NP (_( 2.8_CD +-_NN 0.4_CD ,_, n_NN =_SYM 8_CD )_) ._SENT Aldosterone_NN ,_, compared_VBN with_IN vehicle_NN ,_, significantly_RB increased_VBN Ki-RasA_NP ,_, and_CC Ki-RasA:GTP_NP levels_NNS (_( p_NN <_0.005 =_SYM 4_CD )_) ._SENT At_IN 1_CD and_CC 5_CD min_NN ,_, MAPK_NP activity_NN was_VBD 1.4_CD +-_NN 0.2-_CD and_CC 3.3_CD +-_NN 0.8-fold_NN higher_JJR (_( n_NN =_SYM 2_CD )_) ,_, respectively_RB ._SENT MAPK_NN activity_NN in_IN response_NN to_TO aldosterone_NN increased_VBD steadily_RB peaking_VBG between_IN 0.5_CD and_CC 2_CD h_NN and_CC waning_VBG after_IN 4_CD h._JJ Figure_NP 2_CD |_SYM Aldosterone_NP increases_NNS MAPK_NP activity_NN ._SENT Aldosterone_NN increases_NNS MAPK_NP activity_NN ._SENT (_( A_NP and_CC B_NP )_) MAPK_NP activity_NN was_VBD assessed_VBN by_IN measuring_VBG phosphorylation_NN of_IN exogenous_JJ MBP_NP ._SENT Exogenous_JJ MBP_NP was_VBD added_VBN to_TO equal_VB amounts_NNS of_IN A6_NP cell_NN lysate_NN from_IN cells_NNS treated_VBN with_IN aldosterone_NN for_IN the_DT indicated_JJ times_NNS (_( in_IN minutes_NNS ,_, A_NP ;_: and_CC hours_NNS ,_, B_NP )_) ._SENT These_DT typical_JJ Western_JJ blots_NNS were_VBD probed_VBN with_IN anti-phospho-MBP_NN antibody_NN ._SENT (_( C_NP )_) Summary_NN graph_NN of_IN such_JJ experiments_NNS ._SENT *p_NN <=_0.05 0.05_CD )_) than_IN that_IN in_IN cells_NNS transfected_VBN with_IN pGL2-TK_NN and_CC treated_VBN similarly_RB (_( ALDO_NP =_SYM 1.0_CD +-_NN 0.2_CD ,_, n_NN =_SYM 6_CD ;_: DEX_NP =_SYM 0.7_CD +-_NN 0.2_CD ,_, n_NN =_SYM 3_CD )_) ._SENT In_IN contrast_NN ,_, luciferase_NN activity_NN in_IN the_DT presence_NN of_IN vehicle_NN was_VBD not_RB different_JJ (_( p_NN =_SYM 0.3_CD )_) between_IN pGL2-TK_NN (_( 0.8_CD +-_NN 0.3_CD ,_, n_NN =_SYM 4_CD )_) and_CC pGL2-TK-rasI/E1_JJ --_: transfected_JJ cells_NNS ._SENT Reporter_NN gene_NN activity_NN in_IN cells_NNS transfected_VBN with_IN the_DT minimal_JJ promoter_NN thymidine_NN kinase_NN luciferase_NN plasmid_NP (_( pGL2-TK_NN )_) or_CC pRL-CMV_NP control_NN plasmid_NN alone_RB was_VBD unaffected_JJ by_IN steroid_NN treatment_NN (_( our_PP$ unpublished_JJ data_NNS )_) ._SENT Figure_NP 5_CD |_SYM rasI/E1_JJ region_NN of_IN c-Ki-ras2_NP is_VBZ sufficient_JJ for_IN steroid_NN responsiveness_NN ._SENT rasI/E1_JJ region_NN of_IN c-Ki-ras2_NP is_VBZ sufficient_JJ for_IN steroid_NN responsiveness_NN ._SENT A6_NP cells_NNS were_VBD transiently_RB transfected_VBN with_IN pRL-CMV_NP plus_CC either_DT control_NN reporter_NN plasmid_NP (_( pGL2-TK_NN )_) ,_, which_WDT contained_VBD firefly_NN luciferase_NN expression_NN driven_VBN by_IN the_DT minimal_JJ thymidine_NN kinase_NN promotor_NP ,_, or_CC reporter_NN plasmid_NN that_WDT contained_VBD the_DT rasI/E1_JJ region_NN (_( pGL2-TK-rasI/E1_JJ )_) ._SENT Luciferase_NN activity_NN in_IN cells_NNS treated_VBN with_IN vehicle_NN ,_, aldosterone_NN ,_, and_CC aldosterone_NN plus_IN RU486_NP was_VBD quantified_VBN 48_CD h_NN after_IN transfection_NN ._SENT *p_NN <_SYM 0.05_CD vs._NN pGL2-TK_NN treated_VBN with_IN aldosterone_NN and_CC vehicle_NN ,_, and_CC pGL2-TK-rasI/E1_NN treated_VBN with_IN vehicle_NN ._SENT Activation_NN of_IN MAPK_NP Cascade_NP by_IN Aldosterone_NP Is_NP Dependent_NP on_IN Ki-RasA_NP Expression_NP |_SYM Although_IN all_DT of_IN the_DT above-reported_JJ results_NNS support_VBP the_DT idea_NN that_IN aldosterone_NN activates_VBZ Ki-RasA_NP via_IN transcriptional_JJ control_NN mediated_VBN by_IN nuclear_JJ steroid_NN receptors_NNS ,_, it_PP is_VBZ unclear_JJ whether_IN the_DT aldosterone-sensitive_JJ MAPK_NN signaling_VBG reported_VBN in_IN Figures_NNS --_: is_VBZ in_IN fact_NN dependent_JJ on_IN induction_NN of_IN Ki-RasA_NP ._SENT Experiments_NNS in_IN Figure_NN directly_RB test_VB the_DT link_NN between_IN aldosterone-dependent_JJ induction_NN of_IN Ki-RasA_NP and_CC steroid-dependent_JJ activation_NN of_IN MAPK_NP signaling_VBG ._SENT The_DT typical_JJ Western_JJ blots_NNS in_IN Figure_NP A_NP are_VBP of_IN lysates_NNS extracted_VBN from_IN cells_NNS treated_VBN with_IN aldosterone_NN (_( 1.5_CD mum_NN ;_: control_NN )_) and_CC aldosterone_NN after_IN pretreatment_NN (_( 24_CD h_NN ,_, 10_CD muM_NN )_) with_IN sense_NN and_CC antisense_NN Ki-rasA_NP oligonucleotides_NNS ._SENT Use_NN of_IN these_DT oligonucleotides_NNS in_IN A6_NP cells_NNS has_VBZ been_VBN described_VBN previously_RB ._SENT The_DT top_JJ blot_NN in_IN Figure_NP A_NP was_VBD probed_VBN with_IN anti-K-Ras2A_NN antibody_NN and_CC demonstrates_VBZ the_DT efficacy_NN of_IN the_DT antisense_NN oligonucleotide_NN to_TO decrease_VB Ki-RasA_NP levels_NNS ._SENT Ki-RasA_NN levels_NNS in_IN the_DT antisense_NN group_NN were_VBD similar40_JJ %_NN of_IN th_NN 